KFSHRC's In-House CAR-T Manufacturing Positions Saudi Arabia As A Leader In Biotechnology

Dr. Majid Alfayyadh, CEO of King Faisal Specialist Hospital and Research Centre (KFSHRC), highlighted the hospital's achievement in producing and using CAR-T cell therapy domestically. This development signifies a significant step in adopting advanced treatments within Saudi Arabia. Dr. Alfayyadh shared these insights during the ninth Future Investment Initiative (FII9) Conference, underscoring the Kingdom's readiness to embrace cutting-edge therapeutic technologies.

Saudi Arabia is on a path to becoming a global hub for medical innovation by 2040, driven by an ambitious national vision. Dr. Alfayyadh pointed out that this transformation is supported by an integrated research, regulatory, and investment environment that attracts international partners. The rapid approval process by the Saudi Food and Drug Authority, sometimes as quick as 60 days, exemplifies effective governance fostering research and innovation.

The growth of Saudi Arabia's biotechnology sector relies on modern infrastructure, continuous investment, and adaptable regulations that promote innovation. Dr. Alfayyadh emphasized that integrating research, development, clinical trials, and commercialization is crucial for expanding this sector. The Kingdom aims to translate research into practical medical and commercial applications efficiently.

International collaboration plays a vital role in developing Saudi Arabia's biotechnology sector. Strategic partnerships with leading global research centers and companies facilitate knowledge exchange and technology transfer. This collaboration enhances Saudi Arabia's position in the global bio-innovation ecosystem and supports Vision 2030 goals to localize biopharma and expand the knowledge economy.

Dr. Alfayyadh stressed that national talent is essential for a sustainable biotechnology sector. Saudi Arabia invests in nurturing a new generation of scientists through scholarships and specialized training programs. A national GMP-compliant facility is set to launch within two years, further bolstering the country's biosufficiency and fostering an innovation-driven healthcare economy.

KFSHRC has achieved remarkable recognition on both regional and global scales. It ranks first in the Middle East and North Africa and fifteenth globally among the world's top 250 academic medical centers for 2025. Brand Finance has named it the region’s most valuable healthcare brand, while Newsweek lists it among the World’s Best Hospitals 2025, Best Smart Hospitals 2026, and Best Specialized Hospitals 2026.

With inputs from SPA